Pharmaceuticals

Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED

* Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor * Inmagene retains rights to develop and commerciali...

2024-02-02 22:00 1466

World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap

YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on Febru...

2024-02-02 21:30 1897

Results of Phase II Study on Qilu Pharmaceutical's Novel Drug QL1706 Published in Signal Transduction and Targeted Therapy

JINAN, China, Feb. 2, 2024 /PRNewswire/ -- On January 29th, the results of the phase II study on Qilu Pharmaceutical's novel anticancer drug iparomlimab and tuvonralimab (QL1706) were published online inSignal Transduction and Targeted Therapy (Impact Factor=39.3). The study investigated the use ...

2024-02-02 17:34 1485

Fapon and Bio Farma Sign MOU for Medical Innovations

DONGGUAN, China, Feb. 2, 2024 /PRNewswire/ -- On February 1, 2024, Fapon, a global leading life science company, andBio Farma, a state-owned pharmaceutical holding company inIndonesia specializing in vaccines, life science products, and other pharmaceuticals, signed a memorandum of understanding ...

2024-02-02 16:30 1750

Xinhua Silk Road: Pien Tze Huang, Beijing Tong Ren Tang agree to boost bilateral cooperation, promote high-quality development of TCM

BEIJING, Feb. 2, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang) signed a cooperation agreement with Beijing Tong Ren Tang (TRT) Group during the First Conference of Partners of Tong Ren Tang, which was held inBeijing from January 17 to 19. 

2024-02-02 11:14 2161

Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

SINGAPORE, Feb. 1, 2024 /PRNewswire/ -- Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of all types of liver cancer, including hepatocellular carcinoma and...

2024-02-01 17:41 1690

EMA Aesthetics Announces a Long-Term Strategic and Equity Partnership with ROHTO Pharmaceutical, Signalling ROHTO's Acceleration into the Global Aesthetics Market

DUBLIN, Feb. 1, 2024 /PRNewswire/ -- EMA Aesthetics (www.emaaesthetics.com ) a global aesthetics company headquartered inDublin, is delighted to announce a strategic and equity partnership with ROHTO Pharmaceutical ( www.rohto.co.jp/global

2024-02-01 16:00 1712

NX Netherlands Receives IATA CEIV Pharma Certification for Its Warehouse Near Amsterdam Airport Schiphol

TOKYO, Feb. 1, 2024 /PRNewswire/ -- Nippon Express (Nederland) B.V. (hereinafter "NX Netherlands"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired CEIV Pharma certification (*), a quality certification for pharmaceutical transport established by the International Air Transport As...

2024-02-01 14:00 1427

Promising Clinical Results on the World's First Use of BCMA CAR-T to Treat Immune Mediated Necrotizing Myopathy (IMNM) Published on the Proceedings of the National Academy of Sciences (PNAS)

SHANGHAI, NANJING, China and SAN JOSE, Calif., Jan. 31, 2024 /PRNewswire/ -- On Jan. 30, 2024, PNAS published the research paper titled "Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR T-cell therapy." The paper analyzed results using the fully human B ...

2024-02-01 11:07 1484

SoniVie announces enrollment completion in the REDUCED-1 pilot study with TIVUS™ Ultra-Sound Renal Denervation

SoniVie announces enrollment completion in the REDUCED-1 pilot study TEL AVIV, Israel, Feb. 1, 2024 /PRNewswire/ -- SoniVie , an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat a variety of hypertensive diso...

2024-02-01 01:52 1352

Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development

TAIPEI, Jan. 31, 2024 /PRNewswire/ -- Anbogen Therapeutics, a clinical-stage biotechnology company specializing in groundbreaking cancer drug development, today announced the successful completion of its Series A funding round. The lead investor is China Development Industrial Bank (CDIB), with s...

2024-02-01 00:00 1261

Crystal Pharmatech's CDMO Business Unit - Crystal Formulations Services Successfully Passed EU QP Audit

SUZHOU, China, Jan. 31, 2024 /PRNewswire/ -- Recently, Crystal Formulations Services (CFS), the CDMO Business Unit of Crystal Pharmatech has achieved a significant milestone by successfully passing the on-site audit conducted by the European Qualified Person (QP), evaluating its GMP quality syste...

2024-01-31 21:00 1005

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

-  First manufacturing run successful for MFG7 facility at the Ireland site -  Largest manufacturing scale to date achieved by combining four 4,000-liter single-use bioreactors DUNDALK, Ireland, Jan. 31, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Researc...

2024-01-31 17:31 2088

WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development

SHANGHAI, Jan. 30, 2024 /PRNewswire/ -- WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for ADC platfor...

2024-01-31 10:43 2489

Synbio Tech's Innovative Probiotic Approach Revitalizes Gut and Vaginal Microbiota in Pregnant Women with Candidiasis

KAOHSIUNG, Jan. 31, 2024 /PRNewswire/ -- Innovative research and proprietary technologies have placed Synbio Tech, Inc. (1295:TT) at the forefront of the probiotics field. The company's advancements not only enhance probiotic production efficiency but also significantly benefit intestinal health,...

2024-01-31 09:00 1393

GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant

Starts undertaking quality evaluation and characterization of iPSCs in accordance with ISO standards PALO ALTO, Calif. , Jan. 30, 2024 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com ), specializing in induced pluripotent stem cells (iPSCs) an...

2024-01-31 05:46 1286

Universe Pharmaceuticals INC Reports Fiscal Year 2023 Financial Results

JI'AN, China, Jan. 30, 2024 /PRNewswire/ -- Universe Pharmaceuticals INC ("Universe Pharmaceuticals" or the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor inChina, today announced its financial results for the fiscal year endedSeptember 30, 2023. Mr. Gang Lai, Chairman and C...

2024-01-31 05:30 2814

Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study

A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of the ReCET™ System in Adult Patients with Type 2 Diabetes MINNEAPOLIS, Jan. 31, 2024 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company dedicated to improving outcomes in patients with Type 2 D...

2024-01-30 22:00 1342

XtalPi Unveils Ailux: A New Chapter in AI-Powered Biologics Discovery

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- XtalPi Inc. (XtalPi), a globally leading innovative R&D platform company that harnesses the power of artificial intelligence (AI), quantum physics-based computation, and robotic automation to advance the discovery and evolution of groundbreaking th...

2024-01-30 21:00 1182

Singleron launches the AccuraSCOPE® Single Cell Transcriptome

COLOGNE, Germany, Jan. 30, 2024 /PRNewswire/ -- Singleron Biotechnologies, a leader in single cell multi-omic solutions for precision medicine,announced two new commercial product launches : AccuraSCOPE® Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE® Single Cell Full-Length...

2024-01-30 18:05 1101
1 ... 891011121314 ... 291